Back
Severe Cutaneous Adverse Reactions - SCARS
Dr. Oratile Magano | Clinical
Lecture on T cell mediated skin reactions to medication.
| Topic / Title of the Talk | Severe Cutaneous Adverse Reactions - SCARS |
| Field of Medicine | Dermatology |
| Length of the Talk | 37 Mins |
| CPD Accreditation No. | MDB015/MPDP/070/1843 |
| Category of the Talk | Overview |
| CPD Type | Clinical |
| Languages (Translations) & Subtitles | Not Translated |
| Speaker | Dr. Oratile Magano |
Talk Description
"Severe Cutaneous Adverse Reactions (SCARs) are rare but life-threatening, T-cell-mediated hypersensitivity reactions to medications. They are characterised by extensive skin involvement, painful mucosal disease, and, in many cases, significant systemic organ dysfunction. Although uncommon, their sudden onset and rapid progression mean they represent true dermatological and medical emergencies, and they can result in significant morbidity, mortality, and potential long-term complications.
Although first recognised decades ago, SCARs remain among the most feared adverse drug reactions in modern medicine. A wide range of frequently prescribed medications may be implicated, and early clinical features are often subtle or non-specific, leading to delays in diagnosis and management. In healthcare settings with a high burden of polypharmacy and complex comorbid disease, the clinical and resource impact of SCARs is substantial. Early recognition and appropriate management are therefore critical to improving patient outcomes."
Although first recognised decades ago, SCARs remain among the most feared adverse drug reactions in modern medicine. A wide range of frequently prescribed medications may be implicated, and early clinical features are often subtle or non-specific, leading to delays in diagnosis and management. In healthcare settings with a high burden of polypharmacy and complex comorbid disease, the clinical and resource impact of SCARs is substantial. Early recognition and appropriate management are therefore critical to improving patient outcomes."








